Infliximab: Efficacy in psoriasis.
Indian J Dermatol Venereol Leprol
;
2013 July; 79 Suppl(): S25-34
Article
Dans Anglais
| IMSEAR
| ID: sea-147529
ABSTRACT
Moderate to severe psoriasis often needs to be addressed with standard disease modifying therapies such as methotrexate, cyclosporine, acitretin or ultraviolet radiation, which have their potential benefits and limitations. The tumor necrosis factor-alpha (TNF-α) is elevated in psoriatic plaques compared to non lesional skin as well as in the plasma of patients with moderate to severe psoriasis. Infliximab, a TNF-α blocker, has been recommended for the treatment of moderate to severe plaque psoriasis in adults who have failed to respond to these therapies or who cannot tolerate them. Its specific action on the bound and membrane forms of the pro-inflammatory cytokine TNF-α has made it the molecule of choice for obtaining quicker and longer remission in recalcitrant cases. However, the widespread use of infliximab in the Indian subcontinent is limited by its cost. This article reviews the international guidelines for use of infliximab, its dosage patterns, and efficacy in chronic plaque psoriasis, nail psoriasis, erythrodermic psoriasis, and pustular psoriasis as well as Indian experience.
Texte intégral:
Disponible
Indice:
IMSEAR (Asie du Sud-Est)
Sujet Principal:
Psoriasis
/
Asie
/
Humains
/
Facteur de nécrose tumorale alpha
/
Recommandations comme sujet
/
Évolution de la maladie
/
Produits dermatologiques
/
Anticorps monoclonaux
Type d'étude:
Guide de pratique
Pays comme sujet:
Asie
langue:
Anglais
Texte intégral:
Indian J Dermatol Venereol Leprol
Année:
2013
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS